Drug intelligence / Profile preview

EDP-494

Development stage: Phase 1
Lead developer: Enanta Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

EDP-494 is a small molecule cyclophilin inhibitor developed by Enanta Pharmaceuticals for the treatment of chronic hepatitis C virus (HCV) infection. It targets the human host protein cyclophilin A, which is essential for HCV replication, representing a novel host-targeted antiviral approach. Unlike direct-acting antivirals (DAAs), cyclophilin inhibitors like EDP-494 retain potency against DAA resistance-associated variants and are being investigated as potential combination partners to address hard-to-treat or resistant HCV cases. The drug has been evaluated in phase 1 clinical trials involving healthy volunteers and patients with genotype 1 or genotype 3 chronic HCV infection, administered orally once daily[1][2][4][5].

Other names: EDP-494EDP494EDP 494

Targets

PPIA (Peptidyl-prolyl cis-trans isomerase A)

Beyond the preview

Go deeper on EDP-494.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDP-494.

Explore the full profile